Regulus Therapeutics Inc. (RGLS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.240.00 (0.00%)
At close: 4:00 PM EDT

3.15 -0.09 (-2.78%)
After hours: 4:00 PM EDT

People also watch:
PTCTPTLACEMPEPZMTGTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.25
Prev Close3.24
Bid3.23 x 4500
Ask3.24 x 10600
Day's Range3.13 - 3.26
52wk Range2.44 - 10.60
1y Target EstN/A
Market Cap171.14M
P/E Ratio (ttm)-2.72
Beta1.90
Volume175,604
Avg Vol (3m)818,944
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    Regulus to Present at the 2016 Wedbush PacGrow Healthcare Conference

    LA JOLLA, Calif., Aug. 9, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...

  • Capital Cube21 days ago

    ETF’s with exposure to Regulus Therapeutics, Inc. : August 8, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Regulus Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to RGLS-US. Comparing the performance and risk of Regulus Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Regulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016
    Capital Cube24 days ago

    Regulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016

    Categories: Yahoo Finance Click here to see latest analysis Regulus Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Regulus Therapeutics, Inc. – GlaxoSmithKline plc Sponsored ADR, Biogen Inc., Astrazeneca PLC Sponsored ADR, Sangamo BioSciences, Inc. and Bristol-Myers Squibb Company (GSK-US, BIIB-US, AZN-US, SGMO-US and ... Read more (Read more...)